Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
New subdermal implant delivers potent antiretroviral drugs

A novel, subdermal implant delivering potent antiretroviral drugs shows extreme promise in stopping the spread of HIV, researchers report. Scientists say that they have developed a matchstick size implant, similar to a contraceptive implant, that successfully delivers a controlled, sustained release of tenofovir alafenamide up to 40 days in dogs with no adverse side effects.

Published
29 April 2015
From
Science Daily
HIV prevention and risk behaviors follow weekly patterns

The peak time for seeking information on topics related to HIV, such as prevention and testing, is at the beginning of the week, while risky sexual behaviors tend to increase on the weekends and adherence to antiretroviral therapy (ART) is slightly lower on weekends, according to a new analysis.

Published
27 April 2015
From
Eurekalert Medicine & Health
Many people living with HIV willing to take part in cure research, despite its risks

There is a strong interest among people living with HIV in studies towards an HIV cure, with many potential participants willing to consider antiretroviral treatment interruption. Respondents

Published
24 April 2015
By
Roger Pebody
Treatment outcomes no better with single tablet regimens than individual tablets

One pill a day HIV treatments such as Atripla, Stribild and Eviplera have the same rates of virological failure, drug resistance and side-effects as multiple tablet regimens,

Published
23 April 2015
By
Roger Pebody
Meth, Crack, Coke & Ecstasy: Effects on HIV Disease Progression

A team of researchers, in an article published in JAIDS, reported that they found no association between any frequency of stimulant use and mortality, and only a modest association between high-frequency stimulant use and the combined outcomes of mortality and progression to AIDS.

Published
21 April 2015
From
BETA blog
High treatment failure rate among Thai children switching to second-line ART

There is a high treatment failure rate among children taking second-line antiretroviral therapy (ART), Thai investigators report in the online edition of Clinical Infectious Diseases. Therapy was

Published
20 April 2015
By
Michael Carter
Six questions about HIV/AIDS that deserve more attention

As HIV investigators work to control and eradicate the virus worldwide, certain myths or misconceptions about the disease have been embraced, whereas other concepts with merit have been left relatively unexplored, argues American HIV/AIDS researcher Jay Levy, M.D., in a Trends in Molecular Medicine commentary. He calls on fellow researchers to continue questioning and not to lose sight of alternative strategies that could ultimately lead to a sustainable, long-term solution to HIV infection.

Published
15 April 2015
From
Eurekalert Inf Dis
Human immune system can control re-awakened HIV, suggesting ‘kick and kill’ cure is possible

The human immune system can handle large bursts of HIV activity and so it should be possible to cure HIV with a ‘kick and kill’ strategy, finds new research led by UCL, the University of Oxford and the University of North Carolina at Chapel Hill.

Published
14 April 2015
From
University College London press release
Mechanism of action of ABIVAX’s First-in-class anti-HIV drug published today in peer-reviewed journal Retrovirology

ABX464 blocks viral replication by preventing the export of viral RNA from the nucleus to the cytoplasm in infected cells. This transport is normally mediated by a viral protein called Rev, and the activity of Rev is efficiently inhibited by ABX464. Never targeted before, Rev has been postulated of potential interest for HIV treatment for some time, but ABX464 is the first molecule under development aimed at inhibiting it.

Published
14 April 2015
From
ABIVAX press release
Editing HIV out of our genome with CRISPR

In an attempt to render latent HIV completely harmless, UMass Medical School researchers are using CRISPR/Cas9, a powerful gene editing tool, to develop a novel technology that can potentially cut the DNA of the latent virus out of an infected cell.

Published
13 April 2015
From
University of Massacusetts Medical Schoool press release

Filter by country